Ivax Zyprexa Patent Challenge Could Benefit From Paxil Invalidity Ruling

Ivax believes its challenge to Lilly's Zyprexa patent will get a boost from a recent appellate court decision invalidating a GlaxoSmithKline patent claim for Paxil